Although only 5000 new cases of chronic myeloid leukemia (CML) were seen in the United States in 2009, this neoplasm continues to make scientific headlines year-after-year. Advances in understanding the molecular pathogenesis coupled with exciting developments in both drug design and development, targeting the initiating tyrosine kinase, have kept CML in the scientific limelight for more than a decade. Indeed, imatinib, a small-molecule inhibitor of the leukemia-initiating Bcr-Abl tyrosine kinase, has quickly become the therapeutic standard for newly diagnosed chronic phase-CML (CP-CML) patients. Yet, nearly one-third of patients will still have an inferior response to imatinib, either failing to respond to primary therapy or demonstrating progression after an initial response. Significant efforts geared toward understanding the molecular mechanisms of imatinib resistance have yielded valuable insights into the cellular biology of drug trafficking, enzyme structure and function, and the rational design of novel small molecule enzyme inhibitors. Indeed, new classes of kinase inhibitors have recently been investigated in imatinibresistant CML. Understanding the pathogenesis of tyrosine kinase inhibitor resistance and the molecular rationale for the development of second and now third generation therapies for patients with CML will be keys to further disease control over the next 10 years.
Introduction
'The management of chronic myeloid leukemia (CML) has become complex because of the availability of improved diagnostic procedures and life-prolonging treatment strategies.' 1 Although these lines were originally coined before the clinical introduction of tyrosine kinase inhibitors (TKIs), such as imatinib (Gleevec, Novartis, Basel, Switzerland), nearly a decade ago, they are perhaps more apt today than ever. The phase III International Randomized Study of Interferon (IFN) plus cytarabine and STI571 (IRIS) study established imatinib as primary therapy for newly diagnosed chronic phase-CML (CP-CML) patients. 2 Indeed, imatinib demonstrated the power of translational medicine, linking the identification of the pathogenic Bcr-Abl translocation in CML with the potential of computational chemistry to develop small-molecule kinase inhibitors against the oncogenic enzyme. The 8-year update of the IRIS trial was recently presented and continues to demonstrate an event-free survival (EFS) of 81% and an overall survival (OS) of 85%. In addition, leukemia-specific survival was 93% when only CML-related deaths and those before stem cell transplant (SCT) were calculated. 3 Survival advantages over IFN-a and cytarabine could not be calculated in the IRIS trial because nearly 64% of patients crossed over to imatinib in the first 9 months of therapy, but when compared with historical experiences, imatinib demonstrated improved cytogenetic response rates, as well as OS. 4 On the basis of expert opinion of the available data, both the European LeukemiaNet (ELN) consortium and the National Comprehensive Cancer Network have proposed guidelines for the diagnosis and management of patients with CML. [5] [6] [7] Both groups have established definitions of optimal, suboptimal and treatment failures to frontline TKI-based therapies on the basis of the time-dependent hematological and cytogenetic responses. Patients failing to achieve these preset milestones are described as primarily resistant to therapy, whereas those patients losing previously obtained responses are termed secondarily resistant to treatment. The introduction and approval of two additional TKIs, dasatinib (Sprycel, Bristol-Myers Squibb, New York, NY, USA) and nilotinib (Tasigna, Novartis, Basel, Switzerland), have given clinicians and patients additional therapeutic options. Although the cumulative experience with these second-generation TKIs is relatively brief compared with many chemotherapeutic agents in use today, their rapid incorporation into the therapeutic lexicon has necessitated the further development of provisional definitions of responses to these newer agents and recommendations for treating clinicians to follow to ensure optimal outcomes. Thus, the complexity of the management of CML has seemingly progressed over the last decade, challenging clinicians to identify potential mechanisms of resistance and incorporating this information into therapeutic recommendations.
The problem
Compared with results, only a decade ago, an 8-year OS of 85% would likely have been unthinkable in patients with newly diagnosed CML. However, the true incidence of resistance to imatinib may be underappreciated. With a censoring rate of nearly 20%, continued participation of only 55% of the original cohort in the IRIS trial after 8 years, and a relatively relaxed definition of progressive disease, there has been a concern that the IRIS statistics may underestimate the true proportion of resistant disease. Utilizing the cumulative-best hematological and cytogenetic response rates from the IRIS trial together with the 2009 ELN response criteria, approximately 10 and 25% of patients would be considered imatinib-resistant for failing to have achieved a complete hematological response (CHR) by 3 months or a complete cytogenetic response (CCyR) after 18 months of therapy, respectively (Table 1) . 2, 7 Moreover, up to 20% of those patients previously achieving a hematological or cytogenetic response may lose these important milestones, significantly increasing their risk for disease progression. 8 Recent evidence from additional front-line trials supports the notion that a sizable proportion of CP-CML patients are at risk for either primary or secondary imatinib-resistance. de Lavallade et al. 9 reported the outcome of 204 newly diagnosed CP-CML patients treated with 400 mg of imatinib. Patients in this Hammersmith trial had slightly higher risk disease features compared with the IRIS demographics, including: a higher median leukocyte count at diagnosis (140 versus 17.9), lower hemoglobin (11.1 versus 13.0), increased rates of splenomegaly (67.5 versus 23%), marked splenomegaly (25.5 versus 6%) and a high-risk Sokal score (28.9 versus 18.5%). Despite these differences, the outcomes were quite similar, including cumulative best 5-year estimates for CHR (98.5 versus 96%), major cytogenetic response (MCyR) (85.1 versus 88%), CCyR (82.7 versus 81%) and major molecular response (MMR) at 1 year (50.1 versus 53%). However, de Lavallade et al. 9 estimated that an individual's likelihood of remaining in a CCyR while still receiving imatinib 5 years after diagnosis was approximately 63%. Although discrepancies in the definitions used to define treatment failures in these two trials limits direct comparisons, it supports the notion that approximately one-third of newly diagnosed patients may need alternative therapeutic options to imatinib, either due to primary or secondary resistance or medication intolerance.
Baccarani et al. 10 also recently published the experience of 476 newly diagnosed CP-CML patients randomly assigned to imatinib 800 mg/day (n ¼ 319) or 400 mg/day (n ¼ 157). Although data for hematological response rates are unavailable and only 24-month data are available for cumulative rates of CCyR, 24% of patients failed to achieve a CCyR at this later time point, both in the standard-dose imaitnib, as well as high-dose imatinib cohorts. Palandri et al. 11 recently updated the Gruppo
Italiano Malattie e Matologiche dell'Adulto (GIMEMA) experience in three different prospective trials involving 495 CP-CML patients treated with either 400 mg of imatinib (n ¼ 419) or those treated with imatinib 400 mg and IFN-a (n ¼ 76). Again only 24-month cytogenetic data are available to comment on primary resistance rates, but indicate an approximate 20% resistance rate for failing to achieve a CCyR by this time point in both cohorts. The German CML-IV study is a multicenter prospective evaluation of imatinib 800 mg (IM 800) versus standard dose imatinib ± IFN (IM 400 or IM 400 þ IFN) in newly diagnosed CP-CML patients, and an interim abstract analysis was recently presented. 12 A total of 1026 CP patients have been randomized to date, and data from 790 are available for cytogenetic analysis after a median of 25 months for the IM 800 cohort and 42 months for the IM 400 and IM 400 þ IFN groups. The cumulative incidence of CCyRs at 18 months were 69% for IM 400 (n ¼ 259), 76% for IM 800 (n ¼ 241) and 71% for the IM 400 þ IFN cohort (n ¼ 290), again indicating a nearly 25-30% rate of primary resistance. Finally, the French have initiated a prospective clinical trial of imatinib versus imatinib combination therapies for newly diagnosed CP-CML patients. 13 This phase III randomized trial is comparing imatinib 400 mg/day (n ¼ 159) with three additional experimental arms: imatinib 600 mg/day (n ¼ 160), imatinib 400 mg/day combined with subcutaneous cytarabine (ara-C), (20 mg/m 2 /day, d15-28 of 28-day cycles) (n ¼ 158) and imatinib 400 mg/day combined with subcutaneous pegylated INF-a (Peg-IFN2a) (90 mg/week) (n ¼ 159). To date, only 12-month cytogenetic response rates are available and indicate a CCyR in 57, 65, 66 and 71% of patients, respectively, but do not allow for resistance calculations at this time point.
One universal concern surrounding clinical trials is the extra commitment of both practitioners and patients to optimal outcomes, and the fact that they may give superior results when compared with 'real-world' experiences. Lucas and colleagues recently published a retrospective evaluation of 84 CP-CML patients, including 68 patients treated with front-line imatinib at 12 regional hospitals in Northern England.
14 Approximately 51-58% of patients would have been considered imatinib-resistant by failing to achieve a CCyR at 18 months. Together, these seven studies indicate that both primary and secondary resistance to frontline imatinib remains a venerable challenge in a significant minority of newly diagnosed CP-CML patients.
Recent retrospective analyses have emphasized the importance of identifying patients with suboptimal or resistant disease. Alvarado and colleagues retrospectively evaluated the outcomes of 281 newly diagnosed CP-CML patients, 73 previously treated with 400 mg daily of imatinib and 208 previously treated with 800 mg daily at a single institution. 15 The authors analyzed the EFS and transformation-free survival (TFS) of patients deemed as having either a suboptimal or failure response to imatinib according to the 2006 ELN criteria. 5 Patients declared as having a suboptimal (less than a partial cytogenetic response) or treatment failure (less than a CHR) at 6 months had inferior EFS and TFS compared with those deemed as having an optimal responseFa partial cytogenetic response (PCyR). A landmark analysis at 12 months demonstrated a significantly inferior EFS and TFS for those patients with a treatment failureFless than a PCyR. At this same time point, those with a suboptimal response (less than a CCyR) demonstrated a trend toward an inferior EFS, but there was no difference in TFS. Marin and colleagues also retrospectively evaluated clinical outcomes on the basis of the 2006 ELN criteria using a cohort of 224 patients treated at a single institution. 16 Patients with a treatment failure per Indicates that the data are from the CCyR rate at 24 months rather than 18 months.
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Imatinib-resistance in CML D Bixby and M Talpaz   8 guidelines at the 3, 6, 12 or 18 month time points had an inferior progression-free survival (PFS) and OS. Moreover, patients with a suboptimal response at 6 months had an inferior PFS and OS, but there was no significant difference in PFS or OS at the 12-or 18-month time point. Therefore, the discriminatory power of the suboptimal response seems to be in the first 6 months in both the Alvarado and Marin experiences. Although no prospective data yet exist that altering therapy at early time points of inferior responses would have altered these patient's clinical course, two trials have reviewed outcomes on the basis of the degree of relapse at the time of treatment change. Jabbour et al. 17 published response rates to imatinib dose escalation after initial treatment failure. In 84 total patients, a CCyR was seen in 52% of patients whose therapy was altered at the time of cytogenetic failure, but only 5% of these with a hematological failure. Moreover, the EFS, TFS and OS were also statistically different depending upon the degree of the relapse. Quintas-Cardama and colleagues 18 also recently presented evidence that altering therapy earlier in the course of imatinibresistance may increase the likelihood of achieving optimal outcomes with second-line therapy. Data from 293 imatinibresistant patients treated on three different dasatinib clinical trials were retrospectively reviewed, and patient's outcomes were assessed according to the status of their disease at the time of initiation of second-line therapy. Higher rates of MCyR and CCyR were seen in those patients switched at the time of the loss of a previously obtained MCyR versus those switched after having lost their previously obtained CHR. Improved EFS rates were also demonstrated in those undergoing earlier intervention. Thus, utilizing the ELN and/or National Comprehensive Cancer Network criteria early to identify patients with either primary or secondary resistance may lead to improved clinical outcomes.
Possible etiologies for the problem
Resistance to chemotherapy is a recurrent theme in hematology and oncology, but the molecular underpinnings responsible for the resistance, especially in CML, are being identified at an unprecedented rate. It is readily apparent that a major reason for the therapeutic successes of TKIs in CML is the presence of a well-defined molecular target coupled with the selective and efficient targeting of the essential oncogenic pathway. Concurrently, the successfulness of therapies for patients with resistant disease will require an equally efficient understanding of the resistance pathway(s) tied together with targeted inhibitors of these escape mechanisms. Significant strides have been made over the last decade in uncovering the molecular mechanisms of imatinib-resistance in vitro. However, identifying any of these individual resistance mechanisms in a patient does not necessarily indicate its' sole role in clinical imatinib failures.
Because the Bcr-Abl oncogene is necessary and sufficient for the initiation and propagation of CML, inhibition of the Abl kinase presented an optimal target for a molecular-based therapy. [19] [20] [21] Shortly after the clinical introduction of imatinib, a number of imatinib-resistant cell lines were developed, suggesting the potential for either intrinsic or acquired resistance to the therapy. 22 This was rapidly followed by the clinical description of imatinib-resistance in patients, prompting expanded efforts to understand the biology behind these observations. However, as noted previously, the identification of one specific mechanism of resistance in a clinical sample does not necessarily indicate that it, alone, drives clinical progression, and multiple additional modes of resistance may be at play. None-the-less, a discussion of possible molecular mechanism of TKI resistance is warranted, given that several of these pathways drive clinical evaluations and decision-making in patients presenting with imatinib-resistance.
Bcr-Abl duplication
As previously demonstrated in clinical resistance to both cytotoxic and molecularly targeted therapies in other cancers, amplification of the drug target can lead to tumor outgrowth despite adequate drug exposure. le Coutre, Weisberg and Mahon [23] [24] [25] all independently generated imatinib-resistant clones through serial passage of the cells in imatinib-containing media and demonstrated elevated Abl kinase activity due to a genetic amplification of the Bcr-Abl sequence. However, all of these samples were derived in vitro and may not represent a true mode of clinical resistance. Nevertheless, Gorre et al. 26 obtained specimens, directly patients demonstrating imatinib resistance, and using fluorescence in situ hybridization analysis, genetic duplication of the Bcr-Abl gene was identified as one possible source of the resistance. Additional sporadic examples of amplification of the Bcr-Abl sequence have been clinically described, but the majority of patients presenting with either primary or secondary imatinib resistance fail to clinically demonstrate Abl amplification as a primary mode of treatment failure.
Bcr-Abl mutations
Schindler and colleges 27 originally characterized how imatinib interacts with the nucleotide (adenosine triphosphate (ATP))-binding site of the Abl kinase. Their crystal structure also points to a relatively rigid structural requirement for entry and binding of imatinib, which serves as a potential source for drug resistance. Following these in vitro studies, Gorre et al. demonstrated that six out of nine imatinib-resistant blast-crisis CML patients possessed a single-nucleotide substitution in the Abl gene, resulting in a threonine to isoleucine substitution at amino acid 315 (Th 315 -Ile 315 ; T315I). 26 Modeling of the wild-type Abl kinase interacting with imatinib predicted that although the extra hydrocarbon group in the side chain of the isoleucine would still allow ATP binding, it would result in a steric hindrance and prevent imatinib binding. Numerous additional mutations have been subsequently characterized throughout the Abl sequence, including the P-loop, C-helix, SH2 domain, substrate-binding site, A-loop and C-terminal lobe, some even before the initiation of TKI-based therapies. [28] [29] [30] Although mutational frequencies also appear to increase as patients progress from CP through to blast phase disease, their clinical significance may vary from case to case.
Although the total number of reported point mutations continues to grow, their clinical significance in an individual patient may vary. 22 When reviewing outcomes from a cohort of patients with known imatinib-resistance, Nicolini et al. 31 demonstrated a decreased PFS and OS only for those patients harboring P-loop mutations, as well as those with the T315I alteration. In a separate retrospective analysis of imatinib-resistant patients, Jabbour et al. 32 described an increased risk for disease progression associated with Abl mutations, but in their analysis, only non-P-loop mutations were associated with a poorer OS. Branford reviewed the impact of newly identified mutations in a series of 144 patients with either CP-or accelerated phase-CML treated with imatinib. Around 19% of patients developed mutations
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Because previous retrospective studies had identified de novo kinase domain (KD) mutations, Willis and colleagues 29, 30, 34 prospectively assessed the frequency of mutations in imatinibnaive patients with CML, as well as the longer-term clinical significance of these mutations. Utilizing a combination of an allele-specific PCR assay, together with conventional sequencing, mutations were identified in 15 of 66 patients (23%) before therapy, and they were detected in individuals with accelerated and blast phase disease, but not in CP patients. It is interesting that the identification of a mutation utilizing this very sensitive technique was not correlated with either EFS or OS. Moreover, two patients with the T315I mutation were able to achieve a CCyR with imatinib, one of which obtained a complete molecular response, indicating that mutations detected by these very sensitive assays without concurrent signs of resistance may not always predict for clinical progression.
As previously described, the significance of a point mutation may vary from individual to individual. Moreover, whether the mutation is the driving force behind clinical resistance cannot be reliably determined before instituting a change in therapy. When data from 1093 imatinib-resistant or -intolerant CP-CML patients treated under three different dasatinib trials were analyzed, there were no differences in CHR, MCyR or CCyR rates when patients were segregated into groups with mutations compared with those without mutations. 35 When subset data from the international, open-label, randomized Phase II study SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinibFResistant (START-R) trial was analyzed according to the presence of one of the protocol-specified mutations (L248V, G250E, Q252H/R, Y253H/F, E255K/V, T315I/D, F317L and H369P/R), there were more responses to dasatinib than high-dose imatinib, although only two patients with these mutations were treated with imatinib. 36 In patients with imatinib-resistant or -intolerant accelerated phase disease were treated with dasatinib, similar rates of hematological and cytogenetic responses were also seen in those with or without a mutation. 37 For imatinib-resistant or -intolerant patients with either lymphoid or myeloid blast phase-CML (BP-CML), hematological and cytogenetic response rates to dasatinib were independent of the presence or absence of a baseline Bcr-Abl mutation. 38 Likewise, imatinib-resistant or -intolerant CP-CML patients treated with nilotinib demonstrated similar hematological and cytogenetic response rates, when segregated by the presence or absence of a KD mutation. 39 For imatinib-resistant or -intolerant patients with accelerated phase disease treated with nilotinib, rates of hematological and McyR at 6 months did not appear to be statistically different when comparing those patients with or without mutations. 40 However, several studies have demonstrated that for patients demonstrating highly resistant clones (increased half maximal inhibitory concentration (IC 50 ) values), including the T315I mutation, responses are exceedingly uncommon with the currently available TKIs.
However, in vitro data have suggested differential responses to the available TKIs on the basis of the specific mutation in question. Utilizing either proliferation or biochemical assays, IC 50 values have been generated for each of the available kinase inhibitors against specific KD mutations. 41 Several limitations of these tables have been noted, including the fact that no data regarding achievable plasma levels of each drug have been incorporated and no clinical response rates have been included, which would validate the in vitro patterns of resistance. Laneuville and colleagues 42 recently presented data that attempted to incorporate peak plasma levels (C max ) routinely clinically obtained, together with the in vitro cellular data, in addition to clinical outcomes for patients with specific mutations. However, these data presumes that only peak drug levels correlate with response, and the only clinical data incorporated into this table was complete cytogenetic response rates, which may underreport clinical activity. Bradford and colleagues 43 also reviewed their own clinical data together with the published literature regarding response rates to specific second-generation TKIs in patients with KD mutaitons. They subsequently generated a table of the frequency of clinically relevant mutations on the basis of their frequency in TKI-treated patients and the specific clinical response rates seen with various second-generation TKIs. Unfortunately, very few patients with the T315I mutation are expected to have an appropriate response to clinically available TKIs. Suggesting optimal choices for imatinib-resistant patients solely on the basis of the presence of a specific Abl mutation may be premature and has yet to be incorporated into available guidelines.
Unfortunately, mutations may beget mutations, leading to the theory of a 'mutator phenotype' due to the persistent expression of the Bcr-Abl enzyme. Mutations may be secondary to the generation of reactive oxygen species, altered DNA repair efficiency or activation of additional mutator enzymes by Bcr-Abl. 44 Upon disease progression, additional enzymes, including the activation-induced deaminase, may be expressed, leading to the increased rates of mutations seen in patients with advanced phase disease. 45 Recent evidence also points toward an inherent, a priori genetic phenotype of patients that may be predisposed to imatinib resistance and disease progression. 46 Whether alternative treatment can reduce the risk of progressive in this patient population remains an interesting but unanswered question.
Drug efflux and influx
Numerous additional mechanisms have been proposed to account for imatinib resistance seen in various model systems, although none have been identified as a sole source of clinical resistance leading to progressive disease. As imatinib must bind to the Bcr-Abl kinase, factors that affect intracellular concentrations of the compound may influence its efficacy. It is relatively well established that imatinib is a substrate for the P-glycoprotein (Pgp) efflux pump. 47 Utilizing imatinib-resistant cell lines, Mahon et al. 25 demonstrated an increase in the expression Pgp, although this same cell line also demonstrated a six-fold duplication of the Bcr-Abl sequence, and no distinction between the imatinib resistance contributed by the Abl amplification versus the Pgp overexpression was characterized. Utilizing two different Pgp inhibitors, Che and Kotaki 48, 49 were able to restore imatinib susceptibility in blast phase CML samples. Kotaki and Rumpold 50, 51 utilized an short interfering RNA to downregulate Pgp expression and also restored imatinib susceptibility to resistant cell lines while concurrently demonstrating an increased intracellular concentration of imatinib. However, Langue and colleagues 52 reported a similar clinical response to imatinib in patients with myeloid blast phase CML independent of the level of expression of Pgp in the blasts. Similarly, Crossman et al. 53 failed to find a statistically significant difference between the levels of Pgp in bone marrow mononuclear cells in both pretreatment and post-therapy samples in patients who had achieved a CCyR versus those achieving less than a minor cytogenetic response after 10 months of imatinib therapy, raising the suspicion that Pgp expression itself may not be a clinically relevant predictor of resistance in population studies. However, protein expression levels may not correlate with functionality, and recently, Dulucq and colleagues 54 evaluated polymorphisms in the multidrug resistance sequence and revealed a differential MMR rate to imatinib in three different single-nucleotide polymorphisms, suggesting that different sequences may alter the efficacy of the efflux pump resulting in differential responses to therapy. However, no correlation between different multidrug resistance single-nucleotide polymorphisms and intracellular imatinib levels have been described. There is currently conflicting data as to whether nilotinib is a substrate or an inhibitor of the efflux proteins. [55] [56] [57] Given that intracellular levels of dasatinib increase upon coexposure with nilotinib, there appears to be some degree of active export of dasatinib, but whether this mechanism is clinically relevant remains in doubt. 58 Recently, uptake transporters, especially the organic cation transporter hOCT1, have been investigated as a potential source of imatinib resistance. Several labs have previously demonstrated that imatinib undergoes active import into CML cells through hOCT1. 59 Utilizing a number of CML cell lines, Thomas and colleagues 60 demonstrated a reduced receptor-mediated uptake of imatinib by utilizing inhibitors of the transporter. However, no attempts to correlate the reduced drug levels and a decreased efficacy of imatinib were described. In a follow-up study, White and colleagues 59 did demonstrate a differential in vitro susceptibility to imatinib on the basis of the alterations in hOCT1 functionality, but the significance is perhaps limited by the small number of samples tested and the lack of correlative clinical data. Subsequently, Crossman 53 demonstrated a reduced level of hOCT1 in bone marrow mononuclear cells in patients who had failed to achieve at least a minor cytogenetic response versus those achieving a CCyR after 10 months of imatinib therapy. More recently, Wang and colleagues 61 performed a prospective evaluation of 70 patients with CP-CML through BP-CML and demonstrated a statistically significant difference in the CCyR rate at 6 months, PFS and OS on the basis of the pretreatment hOCT1 expression level as determined by quantitative reverse transcriptase-PCR. Pretreatment ABCB1 (Pgp), ABCG2 and ABCC1 levels did not appear to correlate with these outcomes. The TKI Optimization and Selectivity trial demonstrated that patients with the lowest hOCT1 levels had reduced MMR rates at 12 months when receiving standard dose imatinib compared with those receiving high-dose imatinib. 62 It is interesting that the Trial of Imatinib with Dose Escalation (TIDEL) in chronic myeloid Leukemia trial showed that those patients with the lowest hOCT1 activity had significantly lower PFS, EFS and OS compared with the all other cohorts. 63 It is currently unclear whether hOCT1 levels will influence meaningful differences in the rate of primary imatinibresistance or OS to standard dose imatinib. Other TKIs, such as dasatinib and nilotinib, do not appear to be substrates for hOCT1, but whether this difference alone will lead to reduced resistance rates with these second-generation TKIs remains unknown. 55, 57, 64, 65 
Drug concentration
Numerous chemotherapeutic drugs demonstrate a concentration-dependent response association. Both the concentration, as well as the duration of exposure to the TKI that CML cells must experience for an antileukemic activity is an area of active investigation. Previous work had suggested that CML cells may require at least 16 h of exposure to imatinib to irreversibly commit them to apoptosis, and clinical data had intimated the need to retain trough imatinib concentrations above 1 mM for therapeutic responses. [66] [67] [68] Thus, investigators have focused on trough rather than peak imatinib concentrations as a potential factor in disease resistance. Several manuscripts have proposed a correlation between trough imatinib concentrations and CCyR or MMR rates. In a study presented by Larson et al., 69 CCyR rates appeared to be lower only in the subgroup of patients with trough imatinib concentrations below 647 ng/ml as measured at day 29 of therapy. In a smaller companion study by Picard and colleagues, 70 they found that patients achieving a CCyR had a higher trough imatinib concentration than those not obtaining this milestone (1123±617 versus 694±556 ng/ml; P ¼ 0.03). However, a recent single institution study failed to identify a difference in trough imatinib concentrations in those patients obtaining and those failing to obtain a CCyR or an MMR. 71 As no prospective data exist on the impact of dose intensification in those failing to obtain an optimal imatinib plasma level, the importance of drug-level monitoring will require further validation.
Shah and colleagues 72 originally reported that the duration of exposure to imatinib and dasatinib had a differential effect on the cytotoxicity of a CML cell line, suggesting the capacity of dasatinib to induce apoptosis after a very brief exposure. Snead and colleagues 67 also confirmed that dasatinib treatment in vitro for as short as 4 h resulted in inhibition of substrate phosphorylation and increased apoptosis in both cell lines and primary patient progenitor samples. Brief exposure to nilotinib also resulted in decreased substrate phosphorylation, but had a less predictable impact on apoptosis in a number of cell lines. As previously discussed, intracellular drug concentrations both in the committed myeloid and early progenitor cell populations may vary secondary to active import and efflux of the drug, adding additional variables to the factors affecting cellular resistance on the basis of the plasma drug levels alone. 53, 60, 73 Alternative signaling pathway activation BcrFAbl-mediated cellular transformation alters cell signaling, cell-cell interactions, cell-cycle regulation and apoptosis, by directly and indirectly modulating innumerable signaling cascades. The specific role of each of these pathways is complex and intertwined. In dealing with TKI resistance, one of the most critical factors is identifying whether the disease is still driven by the Bcr-Abl oncogene (oncogene dependent), yet we currently have a very limited capacity to determine the degree to which resistance is oncogene dependent or independent. Identifying assays that would allow clinicians to determine the degree of Bcr-Abl depencency would be invaluable in therapeutic selection. 74, 75 Perhaps the most well-characterized cooperating pathway involves the Src Family Kinases (SFKs), which have been implicated as a factor in altering responsiveness to TKIs, as well as promoting disease progression. 76 SFK activation may also promote a Bcr-Abl independent mechanism of imatinib resistance. [77] [78] [79] [80] Bcr-Abl directly interacts with multiple SFKs that subsequently switches the Abl kinase into an open, active conformation, perhaps permanently altering the enzymes cellular regulation and kinetics. 81 Phosphorylation of the SH2 and SH3 domains of Bcr-Abl by the SFKs may increase the activity of the Abl kinase, thus influencing its susceptibility to 82 Previous studies have demonstrated that in vitro treatment of imatinib-resistant cells with antisense RNA for Lyn partially restored imatinib susceptibility. 78 However, in imatinibresistant patients, there is limited clinical validation that inhibition of only one additional signaling cascade, such as the SFKs, is solely responsible for the clinical activity seen with dasatinib, a dual SFK and Abl kinase inhibitor. Indeed if SFK activation alone could potentiate imatinib resistance, then one could possibly identify clinical specimens that contained Bcr-Abl point mutations, such as the T315I, which would remain dasatinib responsive, given that they would be driven by the SKFs and not by Bcr-Abl, but this is yet to be demonstrated.
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The Bcr-Abl protein also interacts and activates the Ras/Raf/Mek kinase pathway, yet the specific mitogen-activated protein kinase(s) that are subsequently engaged remain to be fully elucidated. [83] [84] [85] One potential pathway involves the recruitment of Raf to the cell membrane, which subsequently activates the Mek1/Mek2 and the extracellular receptor-regulated kinase (Erk) pathways. Grb-2 may directly interact with Bcr-Abl, resulting in recruitment of Gab-2 and leading to the activation of both the phosphatidylinositol 3 0 kinase and Erk pathways. 86 Erk2, but not Erk1, activation may also potentiate the development of imatinibresistance. 87 Activation of the Janus kinase (Jak) and subsequent phosphorylation of several Signal Transducer and Activator of Transcription (STAT) family members has been identified in both Bcr-Abl-positive cell lines and in primary CML cells and may contribute to the transforming ability of Bcr-Abl.
88,89

Epigenetic modification
Gene expression and subsequent protein function can be governed by a balance of epigenetic methylation, as well as post-translational acetylation, respectively. 90 Alterations in the pattern of acetylation of non-histone proteins can promote abnormal cellular proliferation and resistance to apoptosis, which likely potentiates leukemogenesis. Lee and colleagues 91 recently described imatinib resistance in a CML cell line potentially secondary to the upregualtion of Class I and III deacetylases (histone deacetylases) and downregulation of several histone acetyltransferase. Subsequent treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) restored the acetylation pattern of several proteins and altered the apoptotic threshold. In addition, the utilization of histone deacetylase inhibitors, together with TKIs, showed a synergistic effect on the level of apoptosis in primary cells isolated from CML patients. 92, 93 histone deacetylase inhibitors alone have yet to be successfully translated into clinical therapies for imatinib-resistant CP-or AP-CML patients, but are currently being evaluated together with TKIs in an attempt to modulate minimal residual disease. [94] [95] [96] Epigenetic methylation can modulate the expression of genes associated with tumor suppression and apoptosis. It is interesting that the reduced expression of the pro-apoptotic B-cell lymphoma 2 (BCL-2)-interacting mediator was recently identified to be associated with higher rates of primary imatinib resistance. BCL-2-interacting mediator expression was potentially reduced secondary to promoter hypermethylation and could be augmented with 5-aza-2 0 -deoxycytidine (decitabine, Dacogen, Eisai, Tokyo, Japan). Subsequently, cell lines with reduced BCL-2-interacting mediator expression had increased imatinib susceptibility when co-treated with decitabine. Previous clinical trials have demonstrated modest hematological and cytogenetic responses in patients with CML treated with hypomethylating agents alone or in combination with TKIs. 97, 98 It is currently unclear whether treatment with a TKI and a hypomethylating agent in patients with earlier phase disease could augment resistance rates.
Possible solutions to the problem
Primary and secondary resistance to imatinib remains a challenging hurdle both clinically and scientifically. Parsing out the various factors that may contribute to treatment failure is daunting, with only limited guidance from prospective studies. General consensus indicates that patients failing imatinib should be screened for medication compliance, potential drug-drug interactions and Bcr-Abl mutations, with each potentially contributing to the failure. Then, patients may be considered for imatinib dose escalation, transition to a second generation TKI, hematopoietic stem cell transplantation (HSCT) or clinical trial participation. 6, 7, 99 Therapeutic decision making in imatinib-resistant patients is partially scientific, as well as empiric, and may be influenced by previous responses to imatinib, side-effect profiles of the therapeutic options and mutation results. Clearly, additional diagnostic modalities are needed to discriminate between the various resistance mechanisms combined with additional therapeutic options to circumnavigate these pitfalls.
Imatinib dose escalation
Because previous data had indicated a potential dose threshold phenomenon associated with imatinib-mediated enzyme inhibition, resistance may be an acquired phenomenon due to exposure of leukemia cells to subtherapeutic levels of imatinib, either due to inadequate plasma levels or suboptimal intracellular accumulation of the drug. Given that previous phase I testing failed to identify a maximum tolerated dose of imatinib, one potential option to overcome resistance involves imatinib dose escalation. One could potentially reduce the rate of both primary and secondary resistance by initiating treatment with higher doses of imatinib. At least five trials to date have assessed the efficacy of imatinib in CP-CML patients at 600-800 mg/day. Only one has demonstrated an improved TFS compared with historic control cohorts and as previously noted, primary resistance rates, as expressed as the failure to obtain a CCyR by 18 months, do not appear to be significantly improved with dose escalation. 10,13,100-102 Alternatively, two studies have evaluated the efficacy of imatinib dose escalation in patients with secondary resistance to standard dose imatinib. Jabbour et al. 17 reported on 84 patients with secondary imatinib-resistant CP-CML who underwent dose escalation from 400-800 mg of imatinib (n ¼ 72) or 300-600 mg of imatinib (n ¼ 12). Although the 3-year OS rates were 76%, CCyRs were seen in 40% of patients and only 30% maintained a CCyR while still receiving imatinib after 5 years. The median time to a cytogenetic response was 9 months. Moreover, only 5% of those with hemtological resistance to imatinib obtained a CCyR with higher dose therapy. In a randomized phase III trial, Kantarjian and colleagues 36 evaluated switching to dasatinib (70 mg twice daily; n ¼ 101) versus dose escalation of imatinib (400 mg twice daily; n ¼ 49) in 150 patients with secondary resistance to imatinib. After a median follow-up of 26 months, there was no statistical difference in the primary endpoint of a MCyR at 12 weeks in the dasatinib-treated patients (36%) compared with those receiving imatinib (29%) (P ¼ 0.40). However, the rates of CHR, MCyR, CCyR, MMR, PFS and treatment failure were all superior in the dasatinib-treated patients at later time points. Moreover, those patients failing to have any cytogenetic response to 400 mg of imatinib or those failing 600 mg/day of imatinib had inferior cytogenetic responses with imatinib dose escalation compared with conversion to dasatinib. Both studies indicate that imatinib dose escalation is feasible and can provide durable responses, yet caution is warranted especially in those patients failing to achieve any hematological or cytogenetic response to standard dose imatinib.
Second-generation kinase inhibitors
Soon after the clinical introduction of imatinib, cases of primary and secondary resistance were described, forcing researchers to identify compounds that might overcome this hurdle. 26 The initial second-generation TKI clinically evaluated was BMS-354825 (dasatinib), which was identified in a screen of a series of substituted 2-(aminopyridyl)-and 2-(aminopyrimidinyl) thiazole-5-carboxamides that demonstrated potent Src/Abl kinase inhibition with antiproliferative activity in CML cell lines and xenograph models. 103 Although there is significant sequence homology between Abl and Src kinases, imatinib is unable to bind and inhibit the later enzyme. Subsequently, it was identified that dasatinib was able to bind Bcr-Abl in both its open/active, as well as its closed/inactive confirmation. It is also able to bind the Src familiy kinases (SFK) because of a similar geometry to the Abl active confirmation. AMN107 (nilotinib) was subsequently developed by rational drug design based on the crystal structure of an Abl/imatinib complex, allowing researchers to optimize the potency and selectivity of the compound. 104 The net effect is a TKI with higher affinity for Abl, a narrower spectrum of activity against other tyrosine kinases, but with activity against most Abl KD mutations.
The Src/Abl Tyrosine kinase inhibition Activity Research Trials of dasatinib (START) phase II program has demonstrated that dasatinib has activity in all phases of imatinib-resistant CML ( Table 2) . As previously described, the START-R trial evaluated dasatinib 70 mg twice daily compared with imatinib dosed at 400 mg twice daily in resistant CP-CML patients, and demonstrated that dasatinib gave superior rates of CHR, MCyR, CCyR, MMR and PFS beyond 12 weeks. 36 The START-C trial also evaluated dasatinib in 288 imatinib-resistant patients, and demonstrated that 85% of patients had achieved a new CHR, 51% obtained a new MCyR and 40% had achieved a new CCyR, corroborating the results from the START-R trial. 105 Nilotinib has also been evaluated in several trials for patients with imatinib-resistant CP-CML. Kantarjian and colleagues 106 reported on approximately 220 imatinib-resistant CP-CML patients receiving nilotinib 400 mg twice daily, and after a median follow-up of 19 months, 56% achieved a McyR, whereas 41% obtained a CCyR. In an earlier companion study, 16 patients with imaitnib-and dasatinib-resistant CP-CML were evaluated, and 5 (31%) achieved a MCyR (3 CCyR and 2 PCyR). Treatment-Naïve CML Patients (DASISION) trial where 519 newly diagnosed CP-CML patients were randomized to either imatinib 400 mg/day or dasatinib 100 mg daily. There was a trend toward a reduced rate of progression to AP-or BP-disease in those receiving dasatinib versus imatinib (1.9 versus 3.5%), but this was not statistically significant. These findings potentially suggests the best treatment for resistance may be preventing its original occurrence with alternative frontline therapies.
The mechanisms involved in mediating nilotinib resistance remain unknown in many clinical cases. As previously discussed, new Abl mutations have been described in imatinib-resistant patients receiving nilotinib as either second-or third-line therapy. 109, 110 In previous large clinical studies, the collective presence or absence of a KD mutation did not appear to influence the MCyR rate, yet there may be a correlation between the nilotinib IC 50 of a specific mutation and the likelihood of obtaining a MCyR. 39 As previously described, Laneuville 111 reviewed previously published in vitro resistance data for Abl mutations and augmented these values by correcting for clinically achievable in vivo C max for each of the available TKIs, suggesting that nilotinib had the highest likelihood of being clinically active against all, but the T315I mutation. However, previous in vitro data had suggested that with imatinib, and perhaps nilotinib, optimal Abl inhibition for at least 16 h is required for inducing apoptosis, and thus through levels may be more appropraite for clinical determinations of activity. 67 Nilotinib-resistant cell lines have also demonstrated Pgp over expression, Abl amplification and Lyn kinase activation, which may signal why some nilotinib-resistant CML cells may remain sensitive to dasatinib. 56 However, the mechanism responsible for many clinical cases of nilotinib resistance remains an ongoing area of research.
Dasatinib has activity against most imatinib-resistant Abl mutations, as well as demonstrating inhibition of a broad range of tyrosine kinases that may mediate imatinib resistance. 112 When grouped together, the presence or absence of an Abl kinase mutation did not appear to influence the rates of CHR or MCyR in imatinib-resistant patients receiving dasatinib in the previously published START trials. 36, 105 However, specific mutations appear to be differentially resistant to dasatinib both in vitro, as well as in vivo. Jabbour and colleagues also recently demonstrated equivalent response rates to second-generation TKIs when imatinib-resistant patients were grouped according to the presence or absence of a mutation. However, when segregated according to the actual IC 50 of the Abl mutation, patients demonstrating low IC 50 values had a statistically better MCyR, CCyR and PFS compared with those possessing more resistant mutations. 113 Six manuscripts have described the outgrowth of new Abl mutations in imatinib-resistant patients receiving second-line dasatinib. 109, [114] [115] [116] [117] [118] Specifically, Cortes and colleagues 109 detailed the evolution of Abl mutations in patients receiving second and third-line TKI therapy, noting the appearance and disappearance of specific mutations after therapeutic adjustments. As previously emphasized, the etiology of dasatinib resistance in patients failing second-line therapy is potentially independent of the mutations identified and likely reflects activation of alternative survival pathways.
As previously discussed, patients failing imatinib should be screened for compliance, potentially including an assessment of imatinib drug levels. In addition, mutational assessments should be ordered to identify their possible participation on the resistance. Patients failing imatinib can often respond to secondor even third-line TKI-based therapies. 109, 114, 116 The therapeutic decisions can often be assisted by knowing the patient's mutational status, which can evolve over time, and the reported SPOTLIGHT Imatinib-resistance in CML D Bixby and M Talpaz IC 50 for each therapeutic option. Moreover, specific mutations commonly develop after second-line therapies, including mutations at the 299 and 317 loci in those receiving dasatinib, and at positions 253 and 255, 311 and 359 in those receiving nilotinib. Therefore, those with pre-existing P-loop mutations may be more responsive to dasatinib, whereas those with 299 and 317 mutations may benefit from nilotinib. These findings were recently supported by Bradford et al. 43 review of clinical data summarized in their single country retrospective analysis. However, selecting optimal second-and third-line therapy likely includes consideration of the pharmacodynamics of the specific mutations identified together with assessing patients for previous responses to front-line therapies and reviewing potential patientspecific side-effect profiles of the second-generation TKIs.
SCT
For years, allogeneic hematopoietic stem cell transplant (HSCT) was the primary therapeutic option for patients with CML, and in 1999, more than 1000 HSCTs for CML were reported by the European Group for Blood and Marrow transplantation. 99 After the introduction of TKIs, the number of allogeneic transplants for CML significantly declined, and only 434 were performed in 2007. In a large retrospective review of more than 1480 CML patients receiving allogeneic SCT in the pre-TKI era, OS was 47% at 8 years, with a relapse rate of 33% at 5 years. 119 To date, no prospective, randomized trial has yet directly evaluated the role of allogeneic SCT versus TKI-based therapies. However, a prospective randomized study was recently reported that compared outcomes in a cohort of early CP patients randomized to HSCT versus best available drug treatment (INF in combination with hydroxyurea) and demonstrated an improved OS for those receiving medication therapy despite higher rates of CCyR in the transplant population. 120 Recently, a subgroup analysis of the German CML-IV study demonstrated a 91% 3-year survival in those patients undergoing transplant after imatinib failure. 121 on the basis of expert opinion from the ELN, allogeneic transplant may be considered for those patients who have failed a second-line TKI, patients in AP-or BP-CML at the time of diagnosis or upon relapse or those with the T315I mutation. Allogeneic SCT is also an option in those patients who have a suboptimal response to dasatinib or nilotinib as secondline therapy, especially those with a previous hematological Table 2 Response rates to second-generation tyrosine kinase inhibitors in chronic myeloid leukemia Denotes treatment in imatinib-resistant or -refractory patients. c Indicates that the primary endpoint of the study was a MCyR at 12 weeks and there was no significant difference between the patients treated with dasatinib or imatinib. Denotes patients who were resistant to both imaitnib and a second tyrosine kinase inhibitor; NR indicates that the value was not reported.
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resistance to imatinib or those developing mutations while receiving second-line therapy. 7 Some have also considered allotransplant for patients with primary imatinib failure and a high Hammersmith score combined with a low European Group for Blood and Marrow transplantation score. 122 The capacity to couple novel TKIs together with allogenetic SCT in high-risk patients will potentially improve survival, but further research is required.
Third-generation inhibitors
The majority of imatinib-resistant CP-CML patients will not have an identifiable Abl KD mutation. Unfortunately, a majority will also never achieve a CCyR with second-line treatments, and previous retrospective analyses indicate that patients failing to achieve any cytogenetic response at 6 months with secondgeneration TKIs had only a 10% chance of achieving a MCyR at 1 year. Moreover, those failing to achieve a MCyR after 12 months of therapy had a nearly 20% likelihood of disease progression over the subsequent year. 123 Because the median duration of responses to third-line therapies is frequently less than 12 months, additional therapeutic options are urgently needed. Although a profound number of new pathways are being targeted pre-clinically in resistant CML cell lines, the following is a brief description of those agents either currently undergoing or having recently completed clinical trial evaluation in multiple resistant CML patients.
TKIs
The fundamental mechanism of the three currently approved TKIs is that they sterically prevent ATP binding and thus transphosphorylation mediated by the Bcr-Abl kinase. Because of similar three-dimensional structures, these inhibitors often have overlapping activity against alternative kinase pathways. However, their main target remains the leukemia-initiating Bcr-Abl kinase. A number of similarly targeted third-generation TKIs have recently initiated clinical trials evaluation and are reviewed below (Table 3) .
Bosutinib (previously SKI-606, Wyeth, Madison, NJ, USA)
Bosutinib is an orally bioavailable compound that inhibits Bcr-Abl with an approximately 10-to 20-fold higher potency than imatinib, but also possess activity against SFKs, c-Kit and the platelet-derived growth factor receptors. 41, 124 Utilizing a proteomics approach, Rix et al. 125 evaluated the relative specificity of bosutinib for a number of cellular kinases, demonstrating a unique profile of activity when compared with other TKIs. Bosutinib has recently undergone phase II testing. 126 Approximately 137 imatinib-resistant CP-CML patients have been treated to date, and following a median of 8 months of treatment, 79% have achieved a CHR, 40% a MCyR and 29% a CCyR. Although 91% of patients have maintained their MCyR over this time period, the true durability of these responses remains to be determined. Moreover, there is limited information regarding its activity in dasatinib-or nilotinib-resistant patients, thus bringing into question the optimal utilization of this compound in TKI-resistant patients. However, bosutinib has recently completed frontline testing against imatinib, bringing into question its potential use in newly diagnosed patients.
127
AP24534 (Ariad, Cambridge, MA, USA)
As previously described, Abl kinase mutations, including the T315I, are potentially responsible for many cases of clinical resistance. The frequency of the identification of a T315I mutation varies opn the basis of the phase of the disease, but may be as high as 15% in imatinib-resistant CP-CML patients. 128 Because currently available TKIs have no activity against the T315I mutation, a growing number of investigational agents are being clinically evaluated in this patient population. AP24534 is an orally bioavailable multi-kinase inhibitor with activity against a number of kinases, including Bcr-Abl T315, as well as Flt3, c-Kit and the fibroblast growth factor receptor family. 129, 130 After animal model testing demonstrated activity against wild-type CML, as well as a T315I Bcr-Abl cell line, AP24534 has been undergoing phase I testing in multiple hematological malignancies. 131 Talpaz and colleagues 132 recently presented an update from the phase I study, including 42 CML patients, 31 of which were in CP. Around 100% had previously been treated with imatinib, 88% had received dasatinib and 65% had nilotnib. In the 42 evaluable CML patients, 85% achieved a CHR, 48% achieved a McyR, including 33% with a CCyR. All seven of the T315I CP-CML achieved a CHR and 57% obtained a CCyR. The maximum tolerated dose of 45 mg once daily has recently been established and a phase II study is planed beginning late this summer.
INNO-406 (previously NS-187, CytRx, Los Angeles, CA, USA)
This orally bioavailable dual Abl/Lyn kinase inhibitor is approximately 25-55 times more potent than imatinib against Bcr-Abl. In-vitro analysis has also suggested activity against a number of Abl mutations, including multiple P-loop mutations, as well as the F317 alteration. 133 It does not have known activity against the T315I mutation. Recently, Kantarjian et al. 134 reported the results of a phase I clinical trial. A total of 40 patients with imatinib-resistance and 16 with imaitnib-intolerance have been evaluated. A total of 20 patients were also previously treated with nilotinib and 26 with dasatinib, 9 having been treated with both second-generation inhibitors. The maximum tolerated dose was established at 240 mg twice daily, with the dose limiting toxicity being liver function abnormalities and thrombocytopenia. Six patients with CP-CML obtained a MCyR, three of whom obtained a CCyR. Only one of the six responders had an identifiable KD mutation. Further phase II studies are currently planned.
XL228 (Exelixis, South San Francisco, CA, USA)
This intraveniously administered multi-targeted TKI has previously demonstrated in vitro nanomolar-range activity against Abl, SFK, fibroblast growth factor and insulin-like growth factor receptor 1, as well as Aurora kinases A and B. 135 In addition, it appears to have significant in-vitro activity against the T315I mutation. A total of 27 patients with clinical resistance to imatinib, as well as at least one other TKI, have been enrolled in a phase I clinical trial and approximately three-quarters of patients harbor the highly resistant T315I (n ¼ 10), F317L (n ¼ 7) and V299L (n ¼ 3) mutations. At last report, evaluations were occurring with both once-and twice-weekly dosing, and preliminary evidence suggested activity in those receiving 3.6 mg/kg and higher dosing. Hematological or cytogenetic response were reported in 7 of 35 (20%) patients, including three of the nine patients with the T315I mutation reporting a CCyR (n ¼ 1), MCyR (n ¼ 1) and a minor cytogenetic response (n ¼ 1).
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Aurora kinase inhibitors
Unlike normal cells, leukemias often contain a number of karyotypic abnormalities, including evidence of aneuploidy. Several serine/threonine kinases, known as mitotic kinases, regulate the transition from G2 through cytokinesis. In humans, the Aurora kinases A and B appear to have a central role in this process, including responsibilities for centrosome duplication, alignment of chromosomes and mitotic checkpoint arrest. 137 Overexpression of these kinases can be oncogenic, but inhibition can lead to aberrant mitosis resulting in mitotic catastrophe in the leukemia cells.
Danusertib (previously PHA-739358, Nerivano medical sciences, Milan, Italy)
Danusertib is intraveneously available serine-threonine kinase inhibitor with nanomolar activity against Aurora kinases A, B and C, rearranged during transfection, vascular endothelial growth factor receptor 3 (fms-related tyrosine kinase 4, vascular endothelial growth factor receptor 3 (VEGFR3)), and fms-related tyrosine kinase 3. 138 It has also demonstrated in-vitro activity against both wild-type Bcr-Abl and cells possessing the T315I mutation. 139 Preclinical data also suggested activity against CD34 þ CML progenitor cells from previously untreated patients, as well as from those derived from imatinib-resistant 
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AT9283 (Astex, Cambridge, England)
AT9283 is an intraveneously available Aurora kinase A and B inhibitor that also demonstrates nanomolar-range activity against Abl, including the T315I, JAK2, JAK3, GSK3-b, FGFR, VEGFR (Flt4) and Ret. 141, 142 In vitro, leukemia cells exposed to AT9283 form multinucleated, as well as large aneuploidal cells, leading to apoptosis. Utilizing a continuous 72-h IV infusion, 29 patients with acute leukemia, high risk MDSand imatiniband dasatinib-resistant CML were treated at eight different dose levels. Two of the CML patients demonstrated a hematological response, including one who demonstrated a PCyR. On the basis of the pharmacokinetic and pharmacodynamic data, an investigation utilizing an alternative intravenous administration schedule is reportedly proceeding at two sites in the United States.
KW-2449 (Kyowa Hakko Kirin Pharma, Tokyo, Japan) KW-2449 is also an orally bioavailable Aurora kinase A and B inhibitor with concurrent nanomolar range activity against Abl, including the T315I, Flt3 and FGFR1. 143, 144 In a phase I study, KW-2449 was administered between 25-500 mg/day utilizing a twice-daily dosing scheme for 14-days with a 7-28 days rest period. Five imatinib-resistant CML patients were evaluated, three of whom carried the T315I mutation. One BP-CML patient demonstrated a disappearance of the T315I clone and an improvement in their blast count. Pharmacokinetic and dynamic assessments indicated a rapid half-life resulting in inadequate target inhibition resulting in an early termination of the trial. Recently, a new phase I/II trial utilizing doses of 450-800 mg/day in an every 6-8 h dosing scheme is underway, but only in AML patients. 145 It is unclear whether further development in CML is being considered.
Switch pocket inhibitors
DCC-2036 (Deciphera, Lawrence, KS, USA)
A recent class of non-ATP competitive multi-kinase inhibitors, termed switch pocket inhibitors, have recently been developed. Many kinases must undergo a structural alteration between the closed/inactive conformation into an open/active confirmation to accommodate the ATP and substrate undergoing phosphorylation. A key structural feature of the open/active state of Abl enzyme involves the alignment of a stacked array of hydrophobic residues that help stabilize the active structure. Mutations, including the T315I, promote and further stabilize this open confirmation, potentially increasing the activity of the enzyme. The switch pocket inhibitors bind to distinct residues that the Abl kinase uses to undergo the conformational change from the inactive to the active state, and thus keeps the enzyme in the inactive state. Structurally, this would also prevent issues with the steric hindrance that is created by the T315I mutation by avoiding the ATP binding site. 146 The lead compound, DCC-2036, is an orally bioavailable compound with activity against Abl, including the T315I, LYN, HCK, FGR, TIE-2 and VEGFR-2, and a previous CML animal models had suggested significant preclinical activity. Recently, a phase I trail for patients with imatinib-resistant CP-CML or Ph þ ALL has been initiated in three centers in the United States and continues to accrue patients.
Apoptosis modulators
Omacetaxine (Omapro, previously Homoharringtonine, ChemGenex, Victoria, Australia) is a first in class smallmolecule inhibitor believed to augment protein synthesis by binding to the 80S ribosome and interfering with chain elongation. It also appears to induce a disruption of the mitochondrial membrane resulting in a release of cytochrome c and activation of the caspase system. Omacetaxine may also alter the stability of the anti-apoptotic protein MCL-1, which potentiates apoptosis. It appears to function independent of a kinase inhibition activity, thus potentially possessing a clinical role in TKI-resistant patients. A phase II/III study is currently evaluating subcutaneously administered omacetaxine in CP-, AP-or BP-CML patients with resistance and/or intolerance to at least two previous TKIs. 147 A total of 99 patients have been enrolled to date, with clinical data available on 65 patients, 30 with CP-CML, 20 with AP-CML and 15 with BP-CML. A total of 99% of patients had failed imatinib and 57% had failed three or more previous TKIs. Baseline KD mutations were identified in 21 patients (32%). After a median follow-up of 4 months in the CP patients, a CHR was achieved in 18 patients, a MCyR was observed in 6 patients (1 CCyR and 5 PCyR) and a MMR was achieved in 10% of CP-CML patients. In the AP-CML patients, 12 obtained a CHR and one obtained a CCyR. Finally in the BP-CML patients, six achieved a CHR. The clinical trial is ongoing with further updates expected.
In addition to the previously described results, imatinibresistant patients harboring the T315I mutation were enrolled in a separate omacetaxine clinical trial. 148 A total of 90 patients have been enrolled to date, with clinical data available on 66, 40 with CP-CML, 16 with AP-CML and 10 with BP-CML. All patients had failed imatinib, and 79% had failed two or more TKIs. In the CP-CML patients, 26 obtained a CHR, 6 achieved a MCyR and 4 demonstrated a CCyR. Moreover, six obtained a MMR. In the AP-CML patients, five obtained a CHR and one achieved a CCyR. In those patients with BP-CML, two have achieved a CHR. Additional data will obviously be forthcoming from this trial in an attempt to validate the activity in this highly resistant patient population.
Conclusion
The previous pages have clearly reinforced the foreshadowing heralded by Hellman and colleagues when they noted that the management of CML has become increasingly complex because of the availability of improved diagnostic procedures and life prolonging treatment strategies. Imatinib largely initiated the molecular revolution of leukemia therapies by demonstrating that a single TKI could profoundly alter survival in a previously fatal disorder. As is often the case in oncology, clinical resistance developed shortly after the introduction of imaitnib, but investigators have subsequently identified a number of novel
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Imatinib-resistance in CML D Bixby and M Talpaz mechanisms potentially responsible for these failures. Moreover, recent advances in structure-based drug design have facilitated the development of additional kinase inhibitors directed at either overcoming Abl kinase mutations or inhibiting alternative signaling pathways that mediate resistance. The challenge in treating imaitnib-resistant CML remains incorporating vast laboratory data together with patient variables in developing an optimal treatment strategy. However given the pace of the development of alternative treatment strategies, the management of resistant CML is likely to become increasingly complex over the ensuing decade.
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